{"disease":{"id":"epilepsy-seizure","name":"epilepsy seizure"},"drugs":{"marketed":[{"drug_id":"keppra","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xcopri","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xcopri","company_name":"SK Life Science, Inc.","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"topiramate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topamax","generic_name":"topiramate","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tiagabine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gabitril","generic_name":"TIAGABINE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Sodium- and chloride-dependent GABA transporter 1","drug_class":"Anti-epileptic Agent","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"phenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"carbamazepine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"cenobamate","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xcopri","generic_name":"CENOBAMATE","company_name":"Sk Life","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xcopri works by enhancing the activity of a neurotransmitter called GABA, which helps calm down abnormal electrical activity in the brain."},{"drug_id":"levetiracetam","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"carbamazepin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"phenobarbitone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fosphenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"mephenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesantoin","generic_name":"MEPHENYTOIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"primidone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethotoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Peganone","generic_name":"ETHOTOIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dilantin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"topamax","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Topamax","company_name":"Ataturk University","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenacemide","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenurone","generic_name":"PHENACEMIDE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06265103","title":"Epilepsy Learning Healthcare System (ELHS)","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Epilepsy Foundation of America","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05140265","title":"De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT06714448","title":"A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06790810","title":"Observational Study on Dynamic Changes of Blood Pressure During Post-epileptic Seizure Stage (OCBPS)","phase":"","overall_status":"COMPLETED","enrollment_count":1100,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03529045","title":"Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.","phase":"","overall_status":"COMPLETED","enrollment_count":827,"lead_sponsor_name":"LivaNova","has_results":false},{"nct_id":"NCT05267405","title":"Mainz Epilepsy Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT07287163","title":"Clinical Trial of Vormatrigine in Adult Patients With Epilepsy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Praxis Precision Medicines","has_results":false},{"nct_id":"NCT01463306","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT03548779","title":"North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2","phase":"NA","overall_status":"COMPLETED","enrollment_count":548,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT05422664","title":"Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Liu Yonghong","has_results":false},{"nct_id":"NCT05675254","title":"The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients","phase":"","overall_status":"COMPLETED","enrollment_count":494,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT01832038","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"UCB Pharma SA","has_results":true},{"nct_id":"NCT03373383","title":"Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03370120","title":"Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03484039","title":"Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT06741930","title":"Pro-Epileptic Effects of IV Ketamine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Haseki Training and Research Hospital","has_results":false},{"nct_id":"NCT01389596","title":"A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT05725174","title":"Volatile Non-Invasive Biomarkers of Epileptic Seizures","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"University College London Hospitals","has_results":false},{"nct_id":"NCT02477839","title":"Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"UCB BIOSCIENCES, Inc.","has_results":true},{"nct_id":"NCT03739840","title":"A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06922175","title":"REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT07241754","title":"Predictors of Drug Resistant Epilepsy Among Pediatric Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04737837","title":"A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT04252846","title":"A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Eisai Limited","has_results":false},{"nct_id":"NCT04171934","title":"Clinical Validation of a Video-based Epilepsy Examination Service","phase":"","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Tampere University","has_results":false},{"nct_id":"NCT04439656","title":"Detecting Absence Seizures Using Eye Tracking","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Rachel Kuperman","has_results":false},{"nct_id":"NCT04770337","title":"Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Neuroelectrics Corporation","has_results":false},{"nct_id":"NCT06138847","title":"Does Levetiracetam and Carbamazepine Impact the Autonomic Activity of Children With Self-limiting Focal Epilepsy?","phase":"","overall_status":"UNKNOWN","enrollment_count":119,"lead_sponsor_name":"İpek Dokurel","has_results":false},{"nct_id":"NCT04230044","title":"A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT06960811","title":"Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03116828","title":"A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":true},{"nct_id":"NCT03533374","title":"Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Sándor Beniczky","has_results":true},{"nct_id":"NCT07343609","title":"Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04569708","title":"Sleep Spindles and Memory in Rolandic Epilepsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05500638","title":"Effect of VR-ESMEPP on Parents' Seizure Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Akdeniz University","has_results":false},{"nct_id":"NCT03457961","title":"Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03753035","title":"Observance of Anticonvulsant Treatments and Quality of Life of Epileptic Children","phase":"","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05248269","title":"Thermocoagulation in Drug Resistant Focal Epilepsy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","has_results":false},{"nct_id":"NCT04259125","title":"Evaluating the Role of Inflammation in Neonatal Epileptogenesis","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06899230","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"iQure Australia Pty Ltd","has_results":false},{"nct_id":"NCT06608784","title":"Comparison Study of Electrocardiogram Indexes in Patients With Epilepsy, Patients With First Seizure and Normal Population","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Mazandaran University of Medical Sciences","has_results":false},{"nct_id":"NCT02385526","title":"Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Cyberonics, Inc.","has_results":true},{"nct_id":"NCT03283371","title":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06093490","title":"Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT06027749","title":"Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.","phase":"NA","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Epitel, Inc.","has_results":false},{"nct_id":"NCT06310772","title":"Assessing Comorbidities in Epilepsy Using Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT05066880","title":"Yoga and Aerobic Exercise in Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Dokuz Eylul University","has_results":false},{"nct_id":"NCT00275912","title":"Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT05594017","title":"Pharmacological Modulation of Brain Oscillations in Memory Processing","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}